Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Immunovant Inc (Immunovant), a subsidiary of Roivant Sciences Ltd, is a biopharmaceutical company that develops antibodies for the treatment of autoimmune diseases. The company’s pipeline products include IMVT-1402 for graves' disease and anti-citrullinated peptide antibody + difficult-to-treat rheumatoid arthritis; and Baculima treats myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, graves’ disease and thyroid eye disease. The company operates in Switzerland, the UK and the US. Immunovant is headquartered in Durham, North Carolina, the US.
Headquarters
United States of America
Address
Suite 210, 1000 Park Forty Plaza, Durham, North Carolina, 27713
Website
immunovant.com
Telephone
1 917 4103120
No of Employees
315
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IMVT (NASD)
EPS
XYZ
Net Income (2025)
XYZ
-22.2%
(2025 vs 2024)
Market Cap*
$8.0B
* As of and is in US$
Immunovant Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| IMVT-1402: |
| Grave's Disease |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Immunovant Inc | Argenx SE | Hyliion Holdings Corp | Alexion Pharmaceuticals Inc | Momenta Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Netherlands | United States of America | United States of America | United States of America |
| City | Durham | Amsterdam | Cedar Park | Boston | New York City |
| State/Province | North Carolina | Noord-Holland | Texas | Massachusetts | New York |
| No. of Employees | 315 | 1,863 | 113 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Frank M. Torti, M.D. | Chairman | Executive Board | 2021 | 47 |
| Eric Venker, M.D. | Chief Executive Officer; Director | Executive Board | 2025 | 39 |
| Tiago Girao | Chief Financial Officer | Senior Management | 2025 | - |
| Melanie Gloria | Chief Operating Officer | Senior Management | - | - |
| Ruby Grewal | Chief Strategy Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer